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Abstract
Background: Cytomegalovirus (CMV) seronegative recipients (R-) of kidney transplants (KT) from
seropositive donors (D+) are at higher risk for CMV replication and ganciclovir(GCV)-resistance than
CMV R(+). We hypothesized that low CMV-specific T-cell responses are associated with increased risk of
CMV replication in R(+)-patients with D(+) or D(-) donors.
Methods: We prospectively evaluated 73 consecutive KT-patients [48 R(+), 25 D(+)R(-)] undergoing
routine testing for CMV replication as part of a preemptive strategy. We compared CMV-specific
interferon-γ (IFN-γ) responses of CD4+CD3+ lymphocytes in peripheral blood mononuclear cells (PBMC)
using three different antigen preparation (CMV-lysate, pp72- and pp65-overlapping peptide pools) using
intracellular cytokine staining and flow cytometry.
Results: Median CD4+ and CD8+T-cell responses to CMV-lysate, pp72- and pp65-overlapping peptide
pools were lower in D(+)R(-) than in R(+)patients or in non-immunosuppressed donors. Comparing
subpopulations we found that CMV-lysate favored CD4+- over CD8+-responses, whereas the reverse
was observed for pp72, while pp65-CD4+- and -CD8+-responses were similar. Concurrent CMV
replication in R(+)-patients was associated with significantly lower T-cell responses (pp65 median CD4+
0.00% vs. 0.03%, p = 0.001; CD8+ 0.01% vs. 0.03%; p = 0.033). Receiver operated curve analysis associated
CMV-pp65 CD4+ responses of > 0.03% in R(+)-patients with absence of concurrent (p = 0.003) and future
CMV replication in the following 8 weeks (p = 0.036). GCV-resistant CMV replication occurred in 3 R(+)-
patients (6.3%) with pp65- CD4+ frequencies < 0.03% (p = 0.041).
Conclusion: The data suggest that pp65-specific CD4+ T-cells might be useful to identify R(+)-patients
at increased risk of CMV replication. Provided further corroborating evidence, CMV-pp65 CD4+
responses above 0.03% in PBMCs of KT patients under stable immunosuppression are associated with
lower risk of concurrent and future CMV replication during the following 8 weeks.
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Background
Potent immunosuppressive drug regimens have led to a
significant decline of acute and chronic immune reactions
in solid organ transplantation (SOT) with increased graft
survival across HLA mismatches [1,2]. However, compli-
cations associated with impaired immunity have become
more prevalent [3,4]. Cytomegalovirus (CMV) is notori-
ous for exerting direct and indirect effects affecting graft
and patient survival, despite the availability of validated
strategies for prophylactic, preemptive and therapeutic
intervention [5-7]. Persistent CMV replication has been
linked to poor graft outcomes, even in the absence of clas-
sical signs of disease [8-10]. The risk of CMV replication
and disease after SOT is higher in seronegative recipients
R(-) of seropositive donor D(+) organs than in seroposi-
tive R(+) recipients [11] suggesting that CMV-specific
immunity provides a certain degree of protection despite
maintenance immunosuppression. Prophylaxis with oral
ganciclovir (GCV) or valganciclovir (valGCV) has been
recommended for D(+)R(-) high-risk patients [12,13].
However, occurrence of GCV-resistance has been reported
[14,15]. Cytotoxic CD8+ T-cells are thought to play a
major role in terminating CMV replication, while CMV-
specific CD4+ T-cells have been linked to long-term anti-
viral control [16,17]. A better understanding of CMV-spe-
cific T-cell immunity in transplant patients is therefore of
high interest, particularly in the preemptive setting when
prophylaxis is not used. Different CMV antigens and read-
out assays yielded seemingly contradictory results in SOT
recipients [17-24]. Tetramer-based protocols are very sen-
sitive to identify and characterize CMV-specific CD4+ and
CD8+T-cell populations, but restriction to single HLA
antigens and knowledge of epitopes prohibits widespread
application in the clinical routine [25]. This limitation
may be overcome by stimulating T-cells with lysates from
CMV-infected fibroblast or by using synthetic overlapping
15 mer peptide pools covering dominant viral proteins
such as CMV pp65 or pp72 [26]. Flow-cytometry and Elis-
pot assays detecting Interferon-γ (IFNγ) expression have
been used to identify CMV-specific CD4+ and CD8+ T-
cells in recipients of liver [19,20], heart and lung [17,21]
and kidney transplant (KT) [21-24]. Sester found that
increasing calcineurin inhibitor concentrations correlated
with impaired IFNγ-responses to CMV-lysate, and corre-
spondingly lower responses in heart and lung than in KT
patients [23]. Bunde and colleagues reported that pp72-
but not pp65-specific CD8+-responses correlated with
protection from CMV disease, but not from CMV replica-
tion in heart and lung transplant patients [17]. However,
a recent study of 20 D(+)R(-) liver transplants could not
correlate either pp72- or pp65- responses with protection
from CMV disease [19]. By contrast, Lilleri et al. [21]
found that protection from CMV replication of 16 R(+)
SOT recipients (heart, lung, kidney) correlated with strong
T-cell responses when antigens were presented by CMV-
infected autologous dendritic cells. For R(+) KT patients,
Radha et al. [22] demonstrated that pp65-specific CD4+
T-cell responses was associated with rapid CMV clearance
which was also observed for D(+)R(-) patients developing
high CD8+ T-cell responses. We hypothesized that CMV-
seropositive D(+)R(+) and D(-)R(+) KT patients with low
CMV-specific T-cell frequencies are at increased risk for
CMV replication. In view of the controversial informa-
tion, we decided to re-assess the association of CMV-spe-
cific immune responses and CMV replication in the
clinical routine setting and enrolled in 73 consecutive KT
patients undergoing routine testing for CMV replication as
part of the preemptive management followed in our cent-
ers. In patients with persistent CMV replication, we
searched for mutations conferring GCV-resistance in the
CMV UL97 gene.
Patients and methods
Patient population
Consecutive adult CMV D(+)R(-), D(+)R(+) or D(-)R(+)
KT patients (n = 73) were enrolled in this prospective
cross-sectional study. Participants were enrolled in Basel
and in St. Gallen according to the protocol approved by
the internal review board (299/06) in compliance with
the declaration of Helsinki. Patients were entered into the
study if blood was monitored for CMV replication as part
of a preemptive strategy (Figure 1). No prophylaxis was
administered, but testing of CMV D(+)R(-), and D(+)R(+)
or D(-)R(+), thereafter referred to as R(+) KT patients was
performed bi-weekly for the first 4 months, then monthly
until months 6. Cases with documented CMV replication
were tested weekly until resolution was confirmed (Table
1). D(-)R(-) patients were considered low risk and not
routinely tested. All blood samples including the PBMCs
were taken before intake of daily drugs. Between antiviral
or immunosuppressive drugs and blood sampling were at
least 12 h. Patients were treated with GCV or ValGCV
when CMV replication was documented according to
Preiksaitis et al [12], Sanford Guidelines and renal func-
tion. For values close to the diagnostic cut-off of 1000 cp/
mL, confirmatory testing was done within 1 week. At the
time of sampling, antivirals were administered to 10/25
D(+)R(-) (val-GCV in 9, intravenous GCV in 1; concurrent
CMV replication in 4 cases) and to 12/48 R+ patients (val-
ganciclovir in 12; concurrent CMV replication in 6 cases).
Intravenous GCV was used for in-patients, out-patients
were treated with ValGCV. Oral GCV was never used. 71/
73 patients received de-novo transplantation. 2/73
patients were re-transplanted, but did not develop CMV
replication. At the time of laboratory testing for CMV rep-
lication and cellular immune responses, triple immuno-
suppression was administered in 42 patients (58%; CMV
replication in 7 cases), dual immunosuppression in 24
cases (33.3%, CMV replication in 5 cases) and mono-
therapy was used in 2 cases, 1 with CMV replication. Tac-Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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rolimus was used in 51 patients (71%) with mean trough
levels 8.71 ng/mL, 13 showing CMV viremia (p = 0.038,
compared to not tacrolimus-treated patients; chi-
squared). Mycophenolate mofetil was used in 41 patients
(57%) with mean trough levels of 2.54 ug/mL, 6 showing
CMV viremia (p = 0.311; chi-squared). Sirolimus was
used in 18 patients (25%; mean trough levels 6.92 ng/mL,
no CMV replication), cyclosporine A in 10 patients (14%;
mean trough levels 288 ng/mL, no CMV replication); aza-
thioprine in 14 patients (19%, CMV replication in 3
cases); leflunomide in 3 patients (4.2%; CMV replication
in 3 patients); prednisone in 41 patients (57%; mean dos-
ing 9.3 mg/day; CMV replication in 7 cases). We also
tested 30 non-immunosuppressed healthy donors (HD)
[17 seropositive HD(+): median age 31 (range 22–48), 8
males; 13 seronegative; HD(-): median age 32 (range 27–
60), 9 males].
CMV diagnostic assays
IgG CMV-serology (AxSym™ assay, Abbott Diagnostics,
Baar, Switzerland) was used to identify CMV seropositive
and seronegative individuals. CMV replication was quan-
tified after DNA extraction from EDTA-anticoagulated
whole blood (MagNApure™, Roche-Diagnostics,
Rotkreuz, Switzerland). CMV replication was quantified
by real-time-PCR using the primers TTT TTT CTA GGC
GCT TCC GA and ACA CTG CGG CTT TGT ATT CTT TAT
C, and the FAM-TAMRA labeled probe AGG CGA AGC
CGG CGA CGA (Applied Biosystems, Rotkreuz, Switzer-
land). The linear range of the assay is validated from 10e2
to 10e8 copies (cp)/mL. The limit of detection is 300 cp/
mL, and 1000 cp/mL were used as routine diagnostic cut-
off value. All assays were performed in triplicates. For
quantification, a standard curve was constructed from
Study flow chart Figure 1
Study flow chart. We enrolled patients undergoing testing 
for CMV replication as part of the preemptive management 
strategy. CMV-PCR testing was performed together with the 
measurement of CMV-specific T-cell responses. According 
to the initial CMV PCR results, the patients were divided into 
the 2 groups of CMV replication positive and negative. Fur-
ther viral testing was done and patients were then newly 
assigned to a CMV PCR positive or negative. The corre-
sponding numbers of D(+)R(-) and R(+) are shown.
Patients tested for CMV replication
Total n=73
D+R- n=25
R+   n=48
D+R-
R+
Inital
Subsequent
D+R-
R+
1/9
1/6
8/9
5/6
5/16
7/42
11/16
35/42
9/25
6/48
16/25
42/48
pos neg
CMV PCR
pos neg
CMV PCR
pos neg
CMV PCR
Table 1: Characteristics of CMV replicating and non-replicating kidney transplant patients.
CMV D+R- CMV D+R+/D-R+
Initial CMV replication all yes no all yes no
numbera 2 59 1 64 86 4 2
Age, median years (range) 60 (18–71) 63 (25–71) 59 (18–71) 49 (21–73) 53 (43–70) 43 (21–73)
Gender (m/f) 15/10 6/3 9/7 33/15 5/1 28/14
Sample date, weeks postTx median (range) 18 (2–383) 30 (6–41) 15 (2–383) 27 (2–314) 21 (5–138) 17 (2–314)
Induction (%) 19 (76.0%) 7 (77.8%) 12 (54.5%) 36 (75.0%) 3 (50.0%) 33 (76.7%)
T-cell depleting induction (%) 1 (4.0%) 0 (0.0%) 1 (4.5%) 4 (8.3%) 0 (0.0%) 4 (9.3%)
AR therapy (%) 8 (32.0%) 2 (22.2%) 6 (27.3%) 21 (43.8%) 3 (50.0%) 18 (41.9%)
T-cell depleting AR therapy (%) 3 (12.0%) 0 (0.0%) 3 (13.6%) 11 (22.9%) 2 (33.3%) 9 (20.9%)
Initial CMV load, mean (c/ml)a - 109'900 < 300 - 49'588 < 300
Initial CMV peak, mean (c/ml) - 181'811 < 300 - 90'009 < 300
Later CMV replication (n/total)b - 1/9 5/16 - 1/6 7/42
Later CMV load, mean (c/ml) - 288'001 9'323 - 1'489 72'581
Later CMV peak, mean (c/ml) - 1'240'000 37'260 - 3'387 311'071
Note. Cytomegalovirus (CMV) seronegative KT patients had a D+R- serostatus. CMV seropositive KT patients were D+R+ or D-R+. AR, acute 
rejection; ATG, anti-thymoglobuline.
a Patients are grouped according to CMV replication at initial time-point of testing PCR and T-cell responses and denoted as initial CMV episode.
b Positive PCR testing detected during follow-up was denoted as later CMV episode.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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defined copy number of the cloned targets using 10e6,
10e4, 10e2 cp contained in 5 uL which was added to each
reaction. Since DNA was extracted from 200 μL blood and
eluted into 100 μL (e.g. 2-fold concentration), 5 μL per
assay correspond to 10 μL extracted blood which needed
to be multiplied by 100 to obtain the copy number per mL
blood i.e. 10e8/mL, 10e6/mL, and 10e4/mL. DNA speci-
mens or controls were added as 5 uL to 20 uL containing
300 nM of the respective primer pair, 200 nM of the
respective probe and 12.5 uL of the 2-fold concentrated
commercially obtained using a mastermix containing the
AmpliTaq polymerase, dNTP mix with dUTP replacing
dTTP, Uracyl-N-gylcosylase (Eurogentec, Seraing, Bel-
gium) to yield final volume of 25 μL. Each DNA sample
was also analyzed after spiking with 1000 copies of the
target pCMV1 to monitor for inhibition. The temperature
profile consisted of preincubation at 50°C, 2 min to allow
for enzymatic decontamination of synthetic uracyl-conta-
ing amplicons, followed by 95°C; 15 min for hot-start
activation and 45 cycles of 95°C; 15 sec; 60°C; 60 sec, fol-
lowed by 7 min at 72°C. In case of inhibition or unclear
results, the DNA was extracted once again and assayed as
described. Each PCR assay contained routinely non-tem-
plate controls in triplicates as well as one contamination
control of human blood donor serum which was taken
through the entire process of DNA extraction and assayed
in triplicates.
Clinical GCV-resistance was defined as persistent CMV
replication despite adequate antiviral treatment for > 7
days or as breakthrough replication during prophylaxis
[12]. Genotypic resistance was diagnosed when known
mutations in the CMV UL97 gene were identified using
cycle sequencing after a nested PCR strategy with TGC
TGC ACA ACG TCA CGG TAC ATC and AAA CAG ACT
GAG GGG GCT ACT as outer primers (10 min at 95°C;
then 40 cycles of 30 sec at 95°C, 30 sec at 50°C, 1 minute
at 72°C and 7 minutes extension at 72°C) followed by
amplification of two fragments with CGT TGG CCG ACG
CTA TCA AAT TTC and ACA GCT CCG ACA TGC AAT AAC
G (348 bp), as well as GTG GGT AAC GTG CTG GGC TTT
TG and GTG GGT TTG TAC CTT CTC TGT TGC (518 bp).
(10 min at 95°C; then 40 cycles of 30 sec at 95°C, 30 sec
at 50°C, 1 minute at 72°C and 7 minutes extension at
72°C). Final concentrations in a 50 μL reaction volume
were 1 uM primer, 200 nM dNTP, 1× Pwo buffer, 1U of
Pwo polymerase (Roche, Roche-Diagnostics, Rotkreuz,
Switzerland). The respective amplicons were isolated
from preparative gel electrophoresis for cycle sequencing.
If UL97 sequences indicated multiple CMV mutants, the
amplicons were cloned in pGEM3Zf+ plasmid (Promega,
Wallisellen, Switzerland), and clones were sequenced.
Quantification of CMV specific T cells
Cellular immune responses were tested in the laboratory
without knowledge of the serostatus of donor or recipient.
The results of each patient were determined as the mean
of duplicate testing in a single blood draw. The number of
sampling measurements exceeded the number of patients
because some patients were sampled and tested more
than once during the observation period. The frequency of
CMV-antigen-specific IFNγ-producing T-cells by intracel-
lular cytokine staining was carried out according to a pre-
viously published protocol [16] except that peripheral
blood mononuclear cells (PBMC) instead of whole blood
were used. PBMC were taken before all medication, espe-
cially antiviral treatment and immunosuppressive drugs
and tested for CD69+ IFNγ+ response in CD4+CD3+ and
CD8+CD3+ T-cells after stimulation with three different
CMV-antigens: 1) Lysate preparations from CMV infected
fibroblast cell cultures (4 ug/ml, Virion, Rüschlikon, Swit-
zerland), 2) peptide pool covering the immediate early
protein 1 (pp72), and 3) peptide pool covering the late
gene tegument protein (pp65). The peptide pools con-
sisted of 15 amino acids (aa) long peptides with 11aa
overlaps and were used in a final concentration of 1 ug/ml
(Eurogentec). Added non-infected fibroblast-lysate prepa-
rations served as negative control for CMV-lysate and
RPMI1640 media alone for peptides. Staphylococcal
enterotoxin B (SEB, 1 ug/ml, Sigma-Aldrich, Buchs, Swit-
zerland) served as positive control.
PBMC were recovered either from citrate anti-coagulated
CPT™-vacutainers (Becton Dickinson, Allschwil, Switzer-
land) or from EDTA blood using Lymphprep™ (Axis
Shield, Dundee, Scottland), without notable differences
in the CMV-specific responses or in the unstimulated con-
trol. PBMC were washed twice in phosphate-buffered
saline (PBS) and stimulated with CMV-antigens in pres-
ence of α CD28/α CD49d (1 ug/ml, Becton Dickinson),
tested in serial dilution, data not shown) for total 6 hours
in RPMI 1640 medium (Sigma) with 10% fetal calf serum,
1% penicillin/streptomycin (Gibco, Invitrogen, Basel
Switzerland) and 1% glutamax (Gibco). After two hours
we added brefeldin A (10 ug/ml, Sigma) to prevent IFNγ
secretion. Cells were washed once with PBS (without Ca2+
and Mg2+, pH 7.2), fixed first with 4%, then with 1% para-
formaldehyde, permeabilized with 0.1% saponin (Sigma)
in PBS and stained at room temperature in the dark with
following antibodies: α CD3, α CD4, α CD8, α CD69 and
α IFNγ (all Becton-Dickinson). At least 30'000 CD3+ lym-
phocytes were analyzed on a FACSCanto (Becton-Dickin-
son). The frequency of CMV-specific T-cells was analyzed
for each antigen and was expressed as percentage of CD69
and IFNγ double positive CD4+CD3+ or CD8+CD3+
cells. Negative controls were subtracted to determine the
antigen-specific frequency.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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Data analysis
Data were summarized as mean ± standard deviations (±
SD) or as median and ranges where appropriate. When
Kolmogorov-Smirnov Z Test indicated lack of normal dis-
tribution, nonparametric tests were used such as the
Mann-Whitney U test, Spearman's rho correlation analy-
sis, and paired Wilcoxon test. Categorical markers were
analyzed by Fisher's exact or Pearson's chi-square test.
Binary logistic regression's default and receiver operator
characteristics (ROC) analysis with Youlden's Test was
used to determine cut-off levels of T-cell responses. Two-
sided p-values < 0.05 were considered as statistically sig-
nificant. Bonferroni correction was in multiple test situa-
tions to avoid false level of significance. For statistical
analysis, we used the SPSS 13th version package (SPSS,
Zurich, Switzerland).
Results
Immunosuppression and CMV replication at the time of 
sampling
Seventy-three KT patients undergoing routine testing for
CMV replication were enrolled in the study consisting of
48 D(+)R(+) or D(-)R(+), thereafter referred to as R(+) KT
patients and 25 D(+)R(-) KT patients (Table 1). At the
time of sampling, triple immuno-suppression was admin-
istered in 58%, dual immunosuppression in 33.3%, and
monotherapy was used in 2 cases. CMV replication was
found in 9 of 25 D(+)R(-) KT patients at the time of the
initial CMV immune response test. Subsequent CMV rep-
lication was found in another 5 D(+)R(-) patients during
the follow-up (Figure 1). Six of 48 R(+) KT patients had
CMV replication (reactivation) at the time of initial test-
ing, and subsequent CMV replication was documented in
another 7 R(+) KT patients during the follow-up (Figure
1). CMV replication was more frequent in D(+)/R(-)
patients than in R(+) patients (p = 0.031 Fisher's exact).
CMV-specific cellular immune response in kidney 
transplanted patients
PBMC were stimulated with CMV antigens and the fre-
quency of IFNγ-producing T-cell subsets was recorded
(Table 2). As shown for CMV-lysate (Figure 2), R(+) KT
patients had higher CD4+ and CD8+ T-cell responses than
D(+)R(-) KT patients. This was also observed for CMV
pp65, but the significance level was barely missed for
pp72 stimulated CD8+ T-cells (p = 0.056; Table 2). Non-
immunosuppressed HD(+) had higher CMV-specific IFNγ
T-cell frequencies than R(+) KT patients for CMV-lysate
and pp65 antigens (p < 0.001; Figure 2 and data not
shown), except for pp72 for which a strong trend was
observed (p = 0.055).
We compared the responses to different CMV-antigens in
R(+) KT patients. CMV-lysate specific CD4+ and CD8+ T-
cell responses were correlated with pp65-specific CD4+
and CD8+ T-cell responses (Spearman's rho 0.564, 2-
tailed p < 0.001; and Spearman's rho 0.514, 2-tailed p <
0.001, respectively). No correlation was found between
pp65- and pp72-specific CD4+ T-cells (Spearman's rho
0.133, 2-tailed p = 0.347), or between CMV-lysate specific
and CMV-pp72-specific CD8+ T-cell or CD4+ T-cell fre-
quencies (Spearman's rho 0.091, 2-tailed p = 0.530; and
Spearman's rho -0.263, 2-tailed p = 0.065, respectively).
We concluded that T-cell responses to CMV-lysate and -
pp65 appeared similar in PBMC of KT patients and dif-
fered from those to pp72.
CMV-specific cellular immune responses in seropositive KT 
patients with CMV replication
To investigate associations with viral control, we com-
pared the frequency of CMV-specific IFNγ responses in
R(+) KT patients with and without concurrent CMV repli-
cation. Patients with concurrent CMV replication had on
average lower CMV-specific CD4+ and CD8+ T-cell
responses compared to patients without concurrent CMV
Table 2: Percentage of CMV-antigen specific interferon gamma (IFN-γ) producing CD4+ and CD8+ T-cells in healthy donors and 
kidney transplant patients.
Kidney transplant (KT) patients Healthy donors (HD)
CMV D+R+/D-R+ 
n = 48, m = 79
CMV D+R- 
n = 25, m = 50
p-values* CMV seropositive 
n = 13, m = 19
CMV seronegative 
n = 17, m = 17
p-values*
CMV- CD3+ CD4+ median (range) 0.05 (0.00–4.35) 0.01 (0.00–0.14) < 0.001 1.03 (0.03–6.19) 0.01 (0.00–0.22) < 0.001
lysate CD3+ CD8+ median (range) 0.02 (0.00–1.31) 0.00 (0.00–0.07) 0.003 0.49 (0.00–4.57) 0.00 (0.00–0.56) < 0.001
pp72 CD3+ CD4+ median (range) 0.04 (0.00–0.36) 0.02 (0.00–0.26) 0.027 0.08 (0.01–2.83) 0.00 (0.00–0.03) 0.001
peptides CD3+ CD8+ median (range) 0.05 (0.00–0.68) 0.03 (0.00–0.34) 0.056 0.2 (0.00–3.47) 0.00 (0.00–0.03) 0.002
pp65 CD3+ CD4+ median (range) 0.02 (0.00–0.50) 0.01 (0.00–0.55) 0.013 0.11 (0.00–4.70) 0.00 (0.00–0.02) 0.018
peptides CD3+ CD8+ median (range) 0.02 (0.00–0.62) 0.00 (0.00–0.25) 0.001 0.21 (0.00–2.80) 0.00 (0.00–0.20) 0.009
Note. The results are given as frequencies of CD3+ CD4+ or CD3+CD8+ lymphocytes as detailed in Materials&Methods. The number of 
measurements exceeds the number of patients because some patients were tested at more than one visit. CMV, Cytomegalovirus; HD, healthy 
donors; KT, kidney transplant; n, number of patients; m, number of independent blood sampling and measurements. CMV seronegative KT patients 
had a D(+)R(-) constellation. CMV seropositive KT patients included both D(+)R(+) and D(-)R(+) constellations. (*) Mann-Whitney U test.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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replication (Figure 3; see also Table 3). The differences
were statistically significant for CD8+ as well as for CD4+
T-cell responses to CMV-pp65 peptide antigens. Signifi-
cant differences were also found for CD4+ T-cell responses
to CMV-lysate and for CD8+ T-cell responses to pp72-pep-
tides (Table 3). However, the complementing CD8+ T-cell
responses to CMV-lysate and CD4+ T-cell responses to
pp72 were not significantly different. As indicated above,
CD8+ T-cell responses to CMV-lysate and CD4+ T-cell
responses to pp72 were generally lower suggesting the
possibility of a weaker resolution. We concluded that
overall the data pointed to an inverse relation of CMV-
specific T-cell frequencies and viral replication, which
seemed to be best resolved by the pp65-specific CD4+ T-
cell responses.
To identify a possible cut-off of IFNγ T-cell frequency asso-
ciated with patients being free from concurrent CMV rep-
lication, we subjected the data to ROC analyses (Figure 4).
For CMV-lysate, absence of concurrent CMV replication
was significantly associated with CD4+ T-cell frequencies
of > 0.1% and CD8+ T-cell frequencies of > 0.09%. For
CMV-pp65, significant threshold values for CD4+ and
CD8+ T-cells were both > 0.03%. For CMV-pp72, the cut-
offs for CD4+T-cells was > 0.07% (not significant) and for
CD8+T-cells was > 0.09% (p = 0.011), respectively. As
indicated by the higher area under the curve (AUC) of
0.765, CMV pp65-specific responses > 0.03% seemed to
provide the best discrimination for CD4+ T-cell subsets
with a positive predictive value for CMV pp65 CD4 >
0.03% of 95% and a negative predictive value of 40%
(Figure 4). For CMV-specific CD8 responses, pp72 pro-
vided the highest AUC of 0.690, but CD4 pp65 AUC was
only slightly lower with 0.659 (positive and negative pre-
dictive value of 85% and 39%, respectively).
To investigate the degree of protection for later CMV epi-
sodes, we examined the occurrence of CMV viremia dur-
ing the follow-up period. Seven of 42 R(+) patients
without CMV replication at the initial time-point of meas-
urement had subsequent CMV replication within 8 weeks
(median, range 6 to 56 weeks). Here, pp65-specific CD4+
T-cell frequencies were significantly lower compared to
R(+) patients without later CMV replication (Figure 5; p =
0.042; Mann-Whitney U test). ROC analysis confirmed
that pp65-specific CD4+ T-cell frequencies of > 0.03%
were associated with being free from later CMV replica-
tion over the following 8 weeks (AUC: 0.763, specificity:
100%, sensitivity: 47%, Fisher exact test: p = 0.036, posi-
tive predictive value 100%, negative predictive value
CMV-specific IFNγ positive T-cell response in KT patients Figure 2
CMV-specific IFNγ positive T-cell response in KT 
patients. CMV-lysate-specific interferon-γ responses in 
CMV-seropositive R(+) patients and CMV-seronegative 
D(+)R(-) KT patients. Black bars indicate median, whiskers 
indicate interquartile range. P-values were calculated using 
Mann-Whitney U test. Note: The median was below the ana-
lytical cut-off of 0.01% in the CMV-seronegative D(+)R(-) KT 
patients.
Table 3: Percentage of CMV-antigen specific interferon gamma producing CD4+ and CD8+ T-cells of R+ patients with or without 
concurrent CMV replication.
CMV replicating
 (n = 6/48)
CMV non-replicating 
(n = 42/48)
p-values*
CMV- CD3+CD4+ median (range) 0.02 (0.00–0.38) 0.08 (0.00–4.35) 0.011
lysate (m = 79) CD3+CD8+ median (range) 0.01 (0.00–0.21) 0.02 (0.00–1.31) 0.189
pp72 CD3+CD4+ median (range) 0.04 (0.00–0.22) 0.04 (0.00–0.36) 0.291
peptides (m = 50) CD3+CD8+ median (range) 0.03 (0.00–0.24) 0.07 (0.00–0.68) 0.019
pp65 CD3+CD4+ median (range) 0.00 (0.00–0.14) 0.03 (0.00–0.50) < 0.001
peptides CD3+CD8+ median (range) 0.01 (0.00–0.21) 0.03 (0.00–0.62) 0.033
Note. The results are given as frequencies of CD3+ CD4+ or CD3+CD8+ lymphocytes as detailed in Materials&Methods. The number of 
measurements exceeds the number of patients because some patients were tested at more than one visit. CMV, cytomegalovirus; R, recipient; n, 
number of patients; m, number of measurements. CMV seropositive KT patients included both D+R+ and D-R+ constellations. Mann-Whitney U 
test was used to calculate differences (*)Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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27%). We could not identify a similar cut-off for pp65-
specific CD8+ T-cell responses or for any of the CMV-
lysate or -pp72 responses (data not shown).
Ganciclovir-resistance and CMV-specific cellular immune 
responses
One of 25 D(+)R(-) KT patients (4%) developed persist-
ent CMV replication with CMV syndrome, colitis and clin-
ical resistance to GCV treatment, which was confirmed
virologically by the identification of the CMV UL97 muta-
tion G598S (Figure 6). In R(+)-patients, clinical resistance
to GCV-treatment was identified in 3 out of 48 (6.25%)
cases. CMV-specific T-cells IFNγ responses were < 0.03%
for CMV-pp65 antigens (p = 0.041, two-sided Fisher-
Test). Two of these R(+)-patients developed CMV syn-
drome with thrombocytopenia and CMV colitis, respec-
tively. In the latter patient, we identified 6 coexisting
variants, including three novel in-frame deletions in addi-
tion to a previously reported UL97 del1595-1603 known
to increase the IC50 by 8.4-fold to 22.4 μM GCV (Figure
6).
Discussion
Clinical studies have linked the lack of CMV-specific T-
cells in SOT recipients to an increased risk of CMV replica-
tion and subsequent disease being most striking for CMV
D(+)R(-) SOT patients [13]. CMV R(+) patients also
develop CMV complications [16,17,23] albeit at lower fre-
quencies than CMV D(+)R(-) patients. In this study, we
present evidence that CMV viremia in R(+) KT-patients is
associated with lower CMV-specific T-cell frequencies in
PBMC. Among CD8+T-cells, this association was best cap-
tured by pp72 and pp65-specific responses, whereas in the
CD4+T-cell subset, CMV-lysate and CMV-pp65 specific
responses appeared to resolve this difference more effec-
tively. ROC analysis indicated that pp65-specific CD4+ T-
cell responses showed the highest AUC and seemed to
provide a better trade-off between sensitivity and specifi-
city than the other CMV-specific T-cell responses. Previous
studies suggested that CMV-specific CD4+T-cell responses
reflect long-term CMV surveillance, whereas CD8+T-cell
responses are operative in short-term clearance of CMV
replicating cells. Consistent with this hypothesis, Radha et
al [22] found that D(+)R(-) KT patients who developed
CMV-specific CD8+ T-cell responses cleared CMV replica-
tion more rapidly than patients without this response. In
the latter patients, administration of CMV-hyperimmu-
noglobulin helped to clear CMV viremia suggesting that
humoral immunity contributed to CMV control in
D(+)(R-) patients. The antibody-enhanced clearing could
involve neutralization, but also opsonization enhancing
MHC-II presentation and priming of CMV-specific
CD4+T-cells. Clearly, CMV-hyperimmunoglobulin
deserves further study in cases with persisting CMV repli-
cation, with low specific CD4+T-cells [22] and GCV-resist-
ance [12].
Bunde et al [17] reported that higher pp72-specific CD8+
T-cell frequencies were associated with a decreased risk of
CMV disease, but not CMV replication, during the first
month after heart or lung transplantation (AUC 0.719,
specificity 100%, sensitivity 50%, p = 0.012). No associa-
tion with pp65-specific responses was observed, which
seems discrepant to our results in R(+) KT patients. It
should be pointed out that heart or lung patients are gen-
erally more immunosuppressed and that all patients in
the latter study received induction with antithymocyte
globulin plus steroid pulses. We suspect that thereby, the
kinetics of acute CMV replication were accelerated [5]
such that mounting of a pp72-specific response was not
rapid enough to protect from replication, but still affected
progression to disease. This notion is also in line with the
early pp72-specific CD8+T-cell response in 4 other cases
of primary CMV replication [21]. Clearly, further studies
are required to elucidate the partly divergent results and
dynamics of CMV antigen-specific responses in different
risk and transplant patients [19].
An important caveat of defining the risk of CMV replica-
tion through CMV-specific immune effectors resides in
the dynamic aspect of the virus – host balance which is
exquisitely sensitive to changes of the net state of immu-
CMV-specific IFNγ positive T-cell response in KT patients Figure 3
CMV-specific IFNγ positive T-cell response in KT 
patients. CMV-lysate and CMV-pp65 peptide-induced inter-
feron-γ responses in R(+) KT patients with and without con-
current CMV replication. Note: The median was below the 
analytical cut-off of 0.01% in for the pp65-induced CD 4+ and 
CD8+ responses in patients with concurrent CMV replica-
tion.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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nosuppression. In particular, it cannot be decided
whether the association of lower numbers of CMV-spe-
cific T-cells is the cause or the consequence of CMV repli-
cation. Clearly, positive CMV PCR results in blood
identify patients at higher risk for CMV-associated compli-
cations where CMV replication dynamics may be helpful
to predict the further course [27-29]. Negative CMV PCR
results, however, are difficult to interpret with regard to
future risk. In this study, we observed that pp65-specific
CD4+T-cell frequencies above a threshold of 0.03% were
predictive of a CMV viremia-free time for the following 8
weeks. This threshold yielded a specificity of 100% and
sensitivity of 47%. The high specificity and the positive
predictive value of ≥ 95% suggests clinically value because
a test above this threshold would not put patients at risk
for CMV replication or recurrence. The low negative pre-
dictive value of ≤ 40% appears to flag more patients for
CMV surveillance than needed, but avoiding undiagnosed
replication and progression to disease. Clearly, increasing
calcineurin inhibitor levels, anti-rejection treatments par-
ticularly with antilymphocyte agents and steroid pulses
are known to perturb antiviral immune control with low-
ered CMV-specific T-cell responses [21,23] and subse-
quent CMV replication [30,31]. With this limitation in
mind, CMV pp65-specific CD4+ T-cells might serve as a
dynamic marker of protection for patients on stable
immunosuppression complementing CMV load diagnos-
tics in centers using a preemptive strategy [21-23].
Receiver operating characteristic (ROC) analysis – CMV-specific T-cells protecting from concurrent CMV replication Figure 4
Receiver operating characteristic (ROC) analysis – CMV-specific T-cells protecting from concurrent CMV rep-
lication ROC analysis shows thresholds of protection from concurrent CMV replication for the different CMV antigens 
tested. AUC, Area under the curve; p-value by Fisher exact test; PPV, positive predictive value; NPV, negative predictive value.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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Our systematic comparison of CMV-lysate, -pp65 and -
pp72 responses indicated that all three antigen prepara-
tions provided by and large interchangeable results, but
we detected quantitative and qualitative differences in the
response profiles. First, CMV-lysate responses were higher
than the responses elicited by overlapping 15-mer peptide
pools covering pp65 or pp72. Since control responses to
non-infected fibroblast lysate were generally low and
always subtracted from the individual CMV-lysate
responses, these quantitative differences may reflect the
wider range of CMV antigens contained in CMV-lysate
preparations compared to peptide pools restricted to
pp65 or pp72. Second, CMV-lysate favored CD4+ T-cell
responses, whereas CMV-pp72 peptides favored CD8+ T-
cell responses. The stronger CD4+ response to CMV-lysate
has been reported previously [16,19,32] and may result
from uptake, processing and preferential presentation of
larger number of CMV-lysate antigens in an MHC-class II
context. Sylwester et al [26] documented differences in
immunogenicity among the 213 CMV encoded open
reading frames where CMV pp65 and pp72 clearly repre-
sented dominant antigens. Compared to CMV-lysate, 15
mer peptide pools may be more eligible for direct binding
to MHC-class II and also for processing to 8- to 10 mer
peptides when binding to MHC-class I molecules. How-
ever, the preferential CD8+ over CD4+ response of pp72
peptide pools compared to pp65 cannot be easily recon-
ciled. Possibly, additional sequence-encoded differences
in epitopes, binding, and/or processing between pp65
and pp72 15 mer peptides must be operating as well.
These inherent differences of pp72 inducing weak CD4
and strong CD8 T-cells may also explain the only border-
line resolution observed between our non-immunosup-
pressed HD and KT patients.
Lack of CMV-specific immunity in D(+)R(-) KT- and pan-
creas-KT patients has been associated with an increased
risk of GCV-resistance CMV replication [33]. In our study,
clinical GCV-resistance as defined by Preiksaitis et al [12]
occurred in 1/25 (4%) D(+)R(-) KT patients, at a rate com-
parable to other studies [14,15]. By contrast, the fre-
quency of GCV-resistance in our R(+) KT patients was
with 3/48 (6.25%) higher then reported previously
[14,15]. Mutations in the CMV UL97 phosphotransferase
have rarely been described in R(+) SOT patients to date,
and, to the best of our knowledge, were not reported in KT
patients [15,34]. Among UL97 mutations, A594V and
L595S was identified in 30% and 13.3% of reported cases,
respectively, whereas T569I and G598S mutations are less
frequent [15,34-37]. Interestingly, we identified addition-
ally 6 coexisting mutants in a single patient including
three novel in-frame deletions suggesting the dynamic
emergence of genotypic resistance selection during per-
sistent CMV replication (Figure 6). Radha et al reported
that persisting CMV replication in KT patients with low
CMV-specific T-cell responses is not necessarily due to
GCV-resistance [22]. Our study adds that low CMV-spe-
cific T-cell activity may be a first step towards selecting
antiviral resistance, particularly during episodes of sub-
optimally dosed antivirals in outpatients with changing
renal function.
The limitations of our study are the cross-sectional
approach and, although being one of the largest studies,
the still relatively small sample size of KT patients. We
examined CMV cellular immunity in a preemptive setting,
where CMV replication represents only a surrogate marker
of the risk of CMV disease. CMV replication has been used
as outcome marker in other studies since CMV-disease has
become rare with appropriate antiviral treatment
[21,38,39]. Moreover, CMV replication without overt dis-
ease may still cause indirect effects and recently has been
associated with impaired long-term graft and vasculopa-
thy [8-10]. Nevertheless, 1 of 25 D(+)R(-) and 2 of 48
R(+) of our patients developed CMV disease (1 CMV syn-
drome, 2 CMV colitis). Finally, variations associated with
CMV pp65-specific CD4+ T-cell responses and CMV replica- tion in the following 8 weeks Figure 5
CMV pp65-specific CD4+ T-cell responses and CMV 
replication in the following 8 weeks. X-axis indicates KT 
R(+) patients without CMV replication in the following 8 
weeks versus KT R(+) patients with CMV replication in the 
following 8 weeks. Y-axis shows frequency of IFNγ positive 
T-cells in % after specific stimulation with CMV-pp65 pep-
tides. Black bars indicate median, whiskers indicate interquar-
tile range. P-values by Mann-Whitney U test.Journal of Translational Medicine 2008, 6:29 http://www.translational-medicine.com/content/6/1/29
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the laboratory techniques may preclude the direct adop-
tion of our threshold values by other institutions without
further standardization, since the frequencies of measured
CMV-specific T-cells may vary due to difference in stimu-
lation protocols and degree of immunosuppression in dif-
ferent patients posttransplant. However, our data were
obtained from studying KT patients in a clinical routine
situation and therefore warrant larger, preferably prospec-
tive validation.
Conclusion
Monitoring CMV-specific T-cell frequencies may help to
identify R(+) KT patients at risk for CMV replication and
possibly antiviral resistance. Provided further corroborat-
ing evidence, CMV-pp65 CD4+ responses above 0.03% in
PBMCs of KT patients under stable immunosuppression
are associated with lower risk of concurrent and future
CMV replication during the following 8 weeks. Together
with CMV blood loads, CMV-specific cellular immune
responses may help to capture the dynamic interplay of
the virus – host balance in transplant patients and opti-
mize decisions concerning the dosing and duration of
immunosuppressive and antiviral drugs.
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